Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 9/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800111 | 0.90 | TRPV1 (0.33) | TRPV1 | |
| SCHEMBL6481026 | 0.87 | MAPT (0.36) | — | |
| SCHEMBL5815583 | 0.87 | TRPV1 (0.40) | CCR6TRPV1TNNI3KSCN9AMAPK10 | |
| SCHEMBL6473478 | 0.80 | TRPV1 (0.38) | CCR6TRPV1TNNI3KSCN9AMAPK10 | |
| SCHEMBL5797689 | 0.80 | TRPV1 (0.43) | CCR6TRPV1MAP3K12 | |
| SCHEMBL6478217 | 0.79 | TNNI3K (0.37) | CCR6TRPV1TNNI3KSCN9AMAPK10 | |
| SCHEMBL6033605 | 0.77 | TRPV1 (0.48) | TRPV1KCNH2 | |
| SCHEMBL6033090 | 0.76 | TRPV1 (0.43) | CCR6TRPV1MAP3K12TNNI3K | |
| SCHEMBL6478207 | 0.72 | TNNI3K (0.36) | CCR6TRPV1TNNI3KSCN9A | |
| SCHEMBL5800107 | 0.70 | TRPV1 (0.42) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006038041-A1 | BESYLATE SALTS OF SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2006-04-13 | — | — | WO | claimed |
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | CCR6 983/4885TRPV1 11/4885MAP3K12 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.